MX2016002794A - Compuestos antiproliferativos. - Google Patents
Compuestos antiproliferativos.Info
- Publication number
- MX2016002794A MX2016002794A MX2016002794A MX2016002794A MX2016002794A MX 2016002794 A MX2016002794 A MX 2016002794A MX 2016002794 A MX2016002794 A MX 2016002794A MX 2016002794 A MX2016002794 A MX 2016002794A MX 2016002794 A MX2016002794 A MX 2016002794A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- compositions
- antiproliferative compounds
- present
- kdm5
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000001028 anti-proliverative effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 102000008157 Histone Demethylases Human genes 0.000 abstract 1
- 108010074870 Histone Demethylases Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361874310P | 2013-09-05 | 2013-09-05 | |
| PCT/US2014/054114 WO2015035062A1 (en) | 2013-09-05 | 2014-09-04 | Antiproliferative compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016002794A true MX2016002794A (es) | 2016-09-13 |
Family
ID=51541384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016002794A MX2016002794A (es) | 2013-09-05 | 2014-09-04 | Compuestos antiproliferativos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9505767B2 (https=) |
| EP (1) | EP3041474B1 (https=) |
| JP (1) | JP6336598B2 (https=) |
| KR (1) | KR20160049003A (https=) |
| CN (1) | CN105611933B (https=) |
| CA (1) | CA2922925A1 (https=) |
| MX (1) | MX2016002794A (https=) |
| RU (1) | RU2016112568A (https=) |
| WO (1) | WO2015035062A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2903968T3 (en) | 2012-10-02 | 2017-01-30 | Gilead Sciences Inc | INHIBITORS OF HISTON DEMETHYLASES |
| PE20151667A1 (es) | 2013-02-27 | 2015-11-27 | Epitherapeutics Aps | Inhibidores de histona desmetilasas |
| KR20150130491A (ko) * | 2013-03-13 | 2015-11-23 | 제넨테크, 인크. | 피라졸로 화합물 및 그것의 용도 |
| SG11201701182VA (en) | 2014-08-27 | 2017-03-30 | Gilead Sciences Inc | Compounds and methods for inhibiting histone demethylases |
| RU2684396C2 (ru) | 2014-10-29 | 2019-04-09 | Донг-А Ст Ко., Лтд. | Новые соединения пиридопиримидинона для модулирования каталитической активности гистонлизиндеметилаз (KDMS) |
| EP3294313A4 (en) * | 2015-05-15 | 2019-04-17 | The General Hospital Corporation | METHODS RELATING TO THE PREVENTION AND TREATMENT OF DRUG RESISTANCE |
| JP6832430B2 (ja) | 2016-08-31 | 2021-02-24 | アジオス ファーマシューティカルズ， インコーポレイテッド | 細胞代謝過程の阻害剤 |
| EP3525786A4 (en) * | 2016-10-12 | 2020-03-18 | Merck Sharp & Dohme Corp. | KDM5 INHIBITORS |
| EP3525785B1 (en) * | 2016-10-12 | 2025-08-27 | Merck Sharp & Dohme LLC | Kdm5 inhibitors |
| US11124795B2 (en) | 2017-02-28 | 2021-09-21 | University Of Massachusetts | Genetic and pharmacological transcriptional upregulation of the repressed FXN gene as a therapeutic strategy for Friedreich ataxia |
| CN108947985A (zh) * | 2017-05-22 | 2018-12-07 | 苏州偶领生物医药有限公司 | 用作自噬调节剂的化合物及其制备方法和用途 |
| JP2020531519A (ja) | 2017-08-21 | 2020-11-05 | ナビゲン，インコーポレーテッド | Ａｒｆ６阻害剤及び関連する方法 |
| SG11202002218VA (en) * | 2017-09-15 | 2020-04-29 | Aduro Biotech Inc | Pyrazolopyrimidinone compounds and uses thereof |
| AU2020307544A1 (en) * | 2019-06-24 | 2021-11-18 | Dana-Farber Cancer Institute, Inc. | E3 ligase binders and uses thereof |
| EP3999183A4 (en) * | 2019-07-17 | 2023-11-15 | Ono Pharmaceutical Co., Ltd. | COMPOUNDS HAVING KDM5 INHIBITANT ACTION AND THEIR PHARMACEUTICAL USES |
| CN114728167B (zh) | 2019-11-25 | 2024-03-19 | 安进公司 | 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法 |
| WO2023134692A1 (zh) * | 2022-01-13 | 2023-07-20 | 浙江同源康医药股份有限公司 | 多环类化合物及其用途 |
| WO2023205463A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2024100236A1 (en) | 2022-11-11 | 2024-05-16 | Astrazeneca Ab | Combination therapies for the treatment of cancer |
| WO2025194015A1 (en) * | 2024-03-15 | 2025-09-18 | Dem Biopharma, Inc. | Heteroaryl modulators of gpr84 and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DE69428764T2 (de) | 1993-12-24 | 2002-06-20 | Merck Patent Gmbh | Immunokonjugate |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| WO1996003397A1 (en) | 1994-07-21 | 1996-02-08 | Akzo Nobel N.V. | Cyclic ketone peroxide formulations |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| SI9620103A (sl) | 1995-07-06 | 1998-10-31 | Novartis Ag | Pirolopirimidini in postopki za njihovo pripravo |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| EA001595B1 (ru) | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Необратимые ингибиторы тирозинкиназ |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO1998050038A1 (en) | 1997-05-06 | 1998-11-12 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| BR9814116A (pt) | 1997-11-06 | 2000-10-03 | American Cyanamid Co | Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico |
| EA003786B1 (ru) | 1998-11-19 | 2003-10-30 | Варнер Ламберт Компани | N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ |
| TWI271406B (en) | 1999-12-13 | 2007-01-21 | Eisai Co Ltd | Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same |
| JP4100865B2 (ja) * | 1999-12-13 | 2008-06-11 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 三環式縮合異項環化合物、その製造法およびその医薬 |
| AU2003240488A1 (en) | 2002-06-04 | 2003-12-19 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents |
| US7605155B2 (en) * | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| EP2069351B1 (en) * | 2006-06-20 | 2015-10-28 | AbbVie Inc. | Pyrazoloquinazolinones as parp inhibitors |
| WO2010086040A1 (en) | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
| CN101906105B (zh) | 2009-06-08 | 2013-01-16 | 河北医科大学 | 吡唑并[1，5-a]嘧啶酮衍生物及其药物组合物以及其用途 |
| US10953012B2 (en) | 2011-04-26 | 2021-03-23 | Bioenergenix Llc | Heterocyclic compounds for the inhibition of pask |
| US10392389B2 (en) | 2012-10-25 | 2019-08-27 | Bioenergenix Llc | Heterocyclic compounds for the inhibition of PASK |
| ES2635016T3 (es) * | 2013-03-01 | 2017-10-02 | Fundación Para La Investigación Médica Aplicada | Nuevos compuestos como inhibidores duales de fosfodiesterasas e histonas deacetilasas |
| KR20150130491A (ko) | 2013-03-13 | 2015-11-23 | 제넨테크, 인크. | 피라졸로 화합물 및 그것의 용도 |
-
2014
- 2014-09-04 EP EP14766355.3A patent/EP3041474B1/en active Active
- 2014-09-04 MX MX2016002794A patent/MX2016002794A/es unknown
- 2014-09-04 WO PCT/US2014/054114 patent/WO2015035062A1/en not_active Ceased
- 2014-09-04 CA CA2922925A patent/CA2922925A1/en not_active Abandoned
- 2014-09-04 CN CN201480055129.0A patent/CN105611933B/zh active Active
- 2014-09-04 KR KR1020167008823A patent/KR20160049003A/ko not_active Withdrawn
- 2014-09-04 RU RU2016112568A patent/RU2016112568A/ru not_active Application Discontinuation
- 2014-09-04 JP JP2016540387A patent/JP6336598B2/ja not_active Expired - Fee Related
- 2014-09-04 US US14/477,566 patent/US9505767B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015035062A1 (en) | 2015-03-12 |
| KR20160049003A (ko) | 2016-05-04 |
| JP2016529312A (ja) | 2016-09-23 |
| CN105611933B (zh) | 2019-01-25 |
| HK1221421A1 (zh) | 2017-06-02 |
| US9505767B2 (en) | 2016-11-29 |
| EP3041474A1 (en) | 2016-07-13 |
| EP3041474B1 (en) | 2020-03-18 |
| JP6336598B2 (ja) | 2018-06-06 |
| CN105611933A (zh) | 2016-05-25 |
| CA2922925A1 (en) | 2015-03-12 |
| US20150065522A1 (en) | 2015-03-05 |
| RU2016112568A3 (https=) | 2018-08-08 |
| RU2016112568A (ru) | 2017-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016002794A (es) | Compuestos antiproliferativos. | |
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| AU2019268062A1 (en) | Benzoquinolone inhibitors of VMAT2 | |
| MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| IN2015DN01156A (https=) | ||
| MX365294B (es) | Inhibidores de proteína cinasa dependiente de adn. | |
| PH12016500105A1 (en) | Sulfonamides as modulators of sodium channels | |
| MX364486B (es) | Derivados de piridazinona-amidas. | |
| MX390302B (es) | Oxiesteroles y metodos de uso de los mismos | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| MX2015012850A (es) | Inhibidores de la arginina metiltransferasa y usos de los mismos. | |
| HK1220355A1 (zh) | Mk2抑制劑和其用途 | |
| WO2014179564A8 (en) | Thiazolopyrrolidine inhibitors of ror-gamma | |
| PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
| MX2016003823A (es) | Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma. | |
| UA109868C2 (ru) | Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) | |
| TN2015000519A1 (en) | Small molecule inhibitors of fibrosis | |
| MX2016005760A (es) | Inhibidores de glucogeno sintasa cinasa 3 (gsk-3). | |
| PH12017502051A1 (en) | TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | |
| EA201591360A1 (ru) | Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств | |
| CA2929436C (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
| GEAP201814046A (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
| PH12016500347A1 (en) | Triazolopyridine compounds, compositions and methods of use thereof | |
| MX2020006434A (es) | Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor). | |
| MX2020006436A (es) | Compuestos inhibidores del blanco mecanistico de rapamicina (mtor). |